alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › bibliometric

bibliometric

2 studies tagged bibliometric, dated 2026-05-22 to 2026-10-13. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. From Hypothesis to Clinical Validation: A Bibliometric Mapping of Immunotherapy for Neurodegenerative Proteinopathies (2000-2025) 2026-10-13
  2. Immunotherapeutic Innovations in Alzheimer's Disease: A Bibliometric Landscape of Global Research Trends and Evolution 2026-05-22

Studies

2 studies carry this tag.

Date range

2026

Top journals

  • CNS & neurological disorders drug targets 1
  • Current neuropharmacology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. From Hypothesis to Clinical Validation: A Bibliometric Mapping of Immunotherapy for Neurodegenerative Proteinopathies (2000-2025)

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. CNS & neurological disorders drug targets 2026-10-13 Treatments

    Perhaps the most notable signal is that this accumulated progress now appears to be extending beyond Alzheimer's disease: thematic patterns suggest the same immunotherapeutic logic is beginning to extend toward Parkinson's disease and other proteinopathies.

  2. Immunotherapeutic Innovations in Alzheimer's Disease: A Bibliometric Landscape of Global Research Trends and Evolution

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Current neuropharmacology 2026-05-22 Treatments

    Immunotherapy demonstrates disease-modifying potential in early-stage AD; however, it requires carefully optimized dosing regimens, precise biomarker-guided patient stratification, and integrated combinatorial strategies targeting Aβ, tau, and neuroinflammation.

All topic tags with their study counts